Bajaj Healthcare gets Gujarat FDA nod to manufacture hydhroxychloroquine sulphate

​The company will commence production of hydhroxychloroquine sulphate API in the next 3 weeks at its Vadodara facility and it is estimated to produce 15 Mts of API per month, Bajaj Healthcare said. It has started the production of hydroxychloroquine FDF (tablets) at Vadodara unit and is expected to produce around 1.5 crore hydroxychloroquine sulphate tablets.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news